Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2C | Q14957 | 7/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625800 | 0.87 | GRIN2C (0.46) | GRIN2CMTNR1BLMNAMAPTNPSR1 | |
| SCHEMBL16625794 | 0.81 | PDE4D (0.44) | MTNR1BLMNAMAPTNPSR1 | |
| SCHEMBL16627006 | 0.80 | GRIN2C (0.60) | GRIN2CMTNR1BLMNAMAPTNPSR1 | |
| SCHEMBL16625812 | 0.78 | MTNR1B (0.46) | MTNR1BLMNAMAPTNPSR1TP53 | |
| SCHEMBL12744529 | 0.73 | PDE4D (0.42) | MTNR1B | |
| SCHEMBL16625803 | 0.73 | MTNR1B (0.47) | MTNR1B | |
| SCHEMBL16627023 | 0.73 | GRIN2C (0.59) | GRIN2CMTNR1BLMNAMAPTNPSR1 | |
| SCHEMBL5102988 | 0.72 | GRIN2C (0.59) | GRIN2CMTNR1BTP53 | |
| SCHEMBL16625795 | 0.71 | DRD2 (0.45) | MTNR1BLMNAMAPTNPSR1TP53 | |
| SCHEMBL9587165 | 0.71 | DRD2 (0.66) | GRIN2CMTNR1BLMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | GRIN2C 1317/4885MTNR1B 3582/4885LMNA 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.